Pharsight

Arikayce Kit patents expiration

ARIKAYCE KIT's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8802137 INSMED INC Sustained release of antiinfectives
Apr, 2024

(a month ago)

US9827317 INSMED INC Sustained release of antiinfectives
Apr, 2024

(a month ago)

US7718189 INSMED INC Sustained release of antiinfectives
Jun, 2025

(1 year, 12 days from now)

US8642075 INSMED INC Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
Dec, 2026

(2 years from now)

US8679532 INSMED INC Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
Dec, 2026

(2 years from now)

US8632804 INSMED INC Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
Dec, 2026

(2 years from now)

US8226975 INSMED INC Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
Aug, 2028

(4 years from now)

US9566234 INSMED INC Systems for treating pulmonary infections
Jan, 2034

(9 years from now)

US10251900 INSMED INC Methods for treating pulmonary non-tuberculous mycobacterial infections
May, 2035

(10 years from now)

US9895385 INSMED INC Methods for treating pulmonary non-tuberculous mycobacterial infections
May, 2035

(10 years from now)

US10751355 INSMED INC Methods for treating pulmonary non-tuberculous mycobacterial infections
May, 2035

(10 years from now)

US11446318 INSMED INC Methods for treating pulmonary non-tuberculous mycobacterial infections
May, 2035

(10 years from now)

Arikayce Kit is owned by Insmed Inc.

Arikayce Kit contains Amikacin Sulfate.

Arikayce Kit has a total of 12 drug patents out of which 2 drug patents have expired.

Expired drug patents of Arikayce Kit are:

  • US8802137
  • US9827317

Arikayce Kit was authorised for market use on 28 September, 2018.

Arikayce Kit is available in suspension, liposomal;inhalation dosage forms.

Arikayce Kit can be used as treating mycobacterium avium complex (mac) lung disease in adults as part of a combination antibacterial drug regimen, treating mycobacterium avium complex (mac) lung disease in adults with cystic fibrosis as part of a combination drug regimen, treating mycobacterium avium complex (mac) lung disease in adults as part of a combination drug regimen, treating mycobacterium avium complex (mac) lung disease in non-cystic fibrosis adults as part of a combination antibacterial drug regimen.

The generics of Arikayce Kit are possible to be released after 15 May, 2035.

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-214) Sep 28, 2025
Generating Antibiotic Incentives Now(GAIN) Sep 28, 2030

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using AMIKACIN SULFATE ingredient

Market Authorisation Date: 28 September, 2018

Treatment: Treating mycobacterium avium complex (mac) lung disease in adults as part of a combination drug regimen; Treating mycobacterium avium complex (mac) lung disease in adults as part of a combination anti...

Dosage: SUSPENSION, LIPOSOMAL;INHALATION

More Information on Dosage

ARIKAYCE KIT family patents

Family Patents